Phase 2
N=64
Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department
Nausea and Vomiting
Bottom Line
View on ClinicalTrials.gov: NCT00590317 ↗Enrolled (actual)
64
Serious AEs
6.3%
Results posted
May 2014
Primary outcome: Primary: Vomiting at 0 to 120 Min. — 1; 4 number of participants exp vomiting
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Prochlorperazine (Drug); Ondansetron (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Emory University
- Primary completion
- Sep 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Vomiting at 0 to 120 Min. |
1; 4 | — |
| SECONDARY Nausea at 0 to 120 Min |
16.8; 34.3 | — |
| SECONDARY Akithisia at 0 to 120 Min |
3; 1 | — |
Summary
This study will compare the effect of prochlorperazine and ondansetron for the treatment of nausea and vomiting in the emergency department.
Eligibility Criteria
Inclusion Criteria
- Patients presenting to the ED with at least one of the following
- Nausea
- Vomiting documented in the ED
Exclusion Criteria
- Previous treatment in the ED with Ondansetron, prochlorperazine, promethazine or metaclopramide
- Patients with missed last menstrual period
- Pregnancy
- Age < 18 years old
- Treatment with antineoplastic agents within 7 days prior to randomization
- Irritable bowel syndrome
- Gastroparesis
- Suspected gastrointestinal bleed
- Suspected intestinal obstruction
- Preexisting motor disorder (Restless-leg syndrome or Parkinson's disease)
- Traumatic brain injury upon admission to ED
- Intracranial hemorrhage upon admission to ED
- Patients unable to read, write or communicate in the English language
- Patients leaving the ED against medical advice
Data sourced from ClinicalTrials.gov (NCT00590317). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.